Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma

Background: Bortezomib (BTZ) is a powerful proteasome inhibitor that has been approved for the treatment of haematologic malignancies. Its effectiveness has been assessed against different types of solid tumours. BTZ is ineffective in most solid tumours because of drug resistance, including cholangi...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yuancai Xiang, Man Jia, Yuan Gao, Fang Yang, Teng Wang, Rongyang Dai, Meng Wang, Hongming Miao
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	IMR Press 2024-03-01
Colección:	Frontiers in Bioscience-Landmark
Materias:	cisplatin bortezomib nfe2l1 zeb1 cholangiocarcinoma
Acceso en línea:	https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903106
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!